NASDAQ:DSGN

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN
·····

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN

Design Therapeutics shares fell 2.3% to $10.20 Tuesday amid a broader biotech selloff. No new trial data has been released since the company’s May 18 update on its Phase 1/2 RESTORE-FA trial for Friedreich ataxia. Design reported 16 patients completed treatment with no serious side effects. The company held $222.8 million in cash at the end of March.
June 2, 2026

Stock Market Today

  • Aurora Labs Secures $1 Million Defence Grant to Scale Micro Gas Turbine Production
    June 2, 2026, 8:31 PM EDT. Aurora Labs (ASX:A3D) won a $1 million Defence Industry Development Grant from the Australian Department of Defence to advance manufacturing of its Micro Gas Turbine (MGT) propulsion systems. The company will co-invest an equal amount, totaling $2 million, to acquire a large-format metal 3D printer at its Canning Vale facility. This equipment is critical for scaling production to meet rising demand in defence markets, particularly for autonomous systems and guided weapons. The grant aligns with Australia's Sovereign Defence Industrial Priorities, aiming to strengthen local defence manufacturing and reduce reliance on foreign suppliers. Managing Director Rebekah Letheby described the funding as a pivotal shift from research to high-rate sovereign manufacturing of advanced defence propulsion technologies.